Shilpa Medicare Ltd

The new JV entity would be based in the Kingdom of Saudi Arabia. Leveraging their respective strengths, PPI will contribute its local market expertise, while the Shilpa Group will provide global R&D, manufacturing, and regulatory capabilities. The new limited liability company will be majority owned by PPI (70%), with Koanna holding a 30% stake. The venture represents a significant step in Saudi Arabia's healthcare infrastructure and aligns with the Kingdom's Vision 2030 goals of economic diversification and localizing strategic industries. The partnership will be executed in two key phases to ensure a swift market entry and a robust long-term manufacturing strategy. In the first phase, Shilpa Group will supply finished products in bulk for repackaging at the new JVC's facility. This ensures a rapid market entry for key products. Concurrently, PPI will be responsible for establishing this fully-equipped manufacturing facility with technical input from Shilpa Group. In phase-2, Shilpa Group will execute a full technology transfer of its manufacturing processes to the JV. This will empower the JV to commence local production of finished products. As part of the agreement, Shilpa Group will provide technical support for the transfer of the project site to the JVC. PPI will be responsible for equipping the facility with all necessary infrastructure and packaging equipment to meet international standards. Shilpa Group will be responsible for preparing the complete regulatory registration dossier in compliance with the Saudi Food and Drug Authority (SFDA) and will lead the process of obtaining the necessary market authorization. Vishnukant Bhutada, MD of Shilpa Medicare, said: We are excited to partner with PPI, this JV combines PPI's unmatched local strength with Shilpa's innovative technology to improve healthcare in the Kingdom. PPI is the ideal partner to make our products more accessible. This JV underscores our commitment to Saudi Arabia and will consolidate our presence across the MENA region. Shilpa Medicare is a manufacturer of API, formulation, and development services. The company's consolidated net profit surged to Rs 46.89 crore in the quarter ended June 2025 as against Rs 14.06 crore during the previous quarter ended June 2024. Sales rose 9.90% to Rs 321.46 crore in Q1 FY26 as compared with Q1 FY25. The scrip rose 0.52% to currently trade at Rs 827.75 on the BSE. Powered by Capital Market - Live

Koanna International FZ LLC, UAE (Koanna), a wholly owned subsidiary of Shilpa Medicare, has entered into a definitive agreement with Pharma Pharmaceutical Industries & Biological Products (PPI), a prominent Saudi enterprise to form a new joint venture company based in the Kingdom of Saudi Arabia to build a new pharma manufacturing facility in Saudi Arabia. Under the terms of the JV, Koanna will supply finished formulations in bulk form in phase 1 and in phase 2 carry out technology transfer for manufacturing formulations and enable local production. Shilpa Group will be responsible for preparing the complete regulatory registration dossier in compliance with the Saudi Food and Drug Authority (SFDA) and will lead the process of obtaining the necessary Market Authorization. Powered by Capital Market - Live

Shilpa Medicare announced that the 38th Annual General Meeting(AGM) of the company will be held on 23 September 2025.Powered by Capital Market - Live

Net profit of Shilpa Medicare rose 233.50% to Rs 46.89 crore in the quarter ended June 2025 as against Rs 14.06 crore during the previous quarter ended June 2024. Sales rose 9.90% to Rs 321.46 crore in the quarter ended June 2025 as against Rs 292.51 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales321.46292.51 10 OPM %28.2823.93 - PBDT78.5055.79 41 PBT49.5828.68 73 NP46.8914.06 233 Powered by Capital Market - Live

Shilpa Medicare announced that its wholly-owned material subsidiary, Shilpa Pharma Lifesciences, has fully redeemed its outstanding senior, secured, rated, unlisted, and redeemable Non-Convertible Debentures (NCDs) on 11 August 2025. Accordingly, there are no outstanding NCDs as on date with Shilpa Pharma Lifesciences. Powered by Capital Market - Live

The approval reinforces Shilpa Medicare's commitment to addressing unmet medical needs in hepatology through innovation and evidence‐based solutions. This approval will allow Shilpa to become the first company in the World to launch this novel product in any part of the World for NAFLD. NorUDCA is the first‐in‐class treatment for non‐alcoholic fatty liver disease (NAFLD) in India, addressing a significant unmet medical need. NAFLD is currently the most prevalent liver condition globally, affecting about 25% of the world's population (approximately 1.2 billion people) and impacting an estimated 188 million individuals in India alone. If not managed early, NAFLD may progress to non‐alcoholic steatohepatitis (NASH) and severe liver complications, underscoring the urgent necessity for effective therapy. These results collectively demonstrate a significant improvement in both liver structure and function, confirming NorUDCA's superior efficacy compared to placebo in NAFLD. Vishnukant Bhutada, managing director, Shilpa Medicare, said: We are delighted to receive historic approval for NorUDCA, India's first‐in‐class therapy for NAFLD'making Shilpa the first company globally to obtain approval for NorUDCA in this indication. This milestone is a moment of immense pride for Shilpa and the nation, as we now pioneer the launch of its finished dosage form. This breakthrough exemplifies Shilpa's unwavering dedication to innovation and accessible healthcare to millions battling liver disease in India and beyond. We are excited to introduce NorUDCA tabletsin India immediately, while advancing global regulatory efforts to bring this vital therapy to patients internationally.' Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company's consolidated net profit fell 40.77% to Rs 14.51 crore, while revenue from operations rose 13.40% to Rs 330.80 crore in Q4 FY25 over Q4 FY24. The scrip had advanced 1.46% to end at Rs 831.80 on the BSE on Friday. Powered by Capital Market - Live

Shilpa Medicare announced the approval of its, Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, by  the Central Drugs Standard Control Organization (CDSCO), marking a major milestone in innovative  Non Alcoholic Fatty Liver Disease (NAFLD) therapy  in India.  The approval reinforces Shilpa Medicare'fs commitment to addressing unmet medical needs in hepatology  through innovation and evidence']based solutions. This approval will allow Shilpa to become the first company in  the World to launch this novel product in any part of the World for NAFLD.  NorUDCA is the first']in']class treatment for Non']alcoholic Fatty Liver Disease (NAFLD) in India, addressing a  significant unmet medical need. Powered by Capital Market - Live

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live

Shilpa Medicare Ltd lost 4.48% today to trade at Rs 876.5. The BSE Healthcare index is down 1.93% to quote at 44977.63. The index is up 1.68 % over last one month. Among the other constituents of the index, SMS Pharmaceuticals Ltd decreased 3.98% and Vimta Labs Ltd lost 3.74% on the day. The BSE Healthcare index went up 11 % over last one year compared to the 1.28% fall in benchmark SENSEX. Shilpa Medicare Ltd has added 0.34% over last one month compared to 1.68% gain in BSE Healthcare index and 3.59% drop in the SENSEX. On the BSE, 128 shares were traded in the counter so far compared with average daily volumes of 5123 shares in the past one month. The stock hit a record high of Rs 1003.2 on 16 Jun 2025. The stock hit a 52-week low of Rs 530.5 on 07 Apr 2025.Powered by Capital Market - Live

The good manufacturing practice (GMP) inspection was conducted from 24 October 2024 to 30 October 2024. This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - oral dissolving films and transdermal systems. The Unit is already approved by EMA, Europe; MHRA, UK; SFDA, Saudi and TGA, Australia. This Unit is currently supplying Oral Film products to US and other markets. Transdermal products have been filed in the European market. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company's consolidated net profit fell 40.77% to Rs 14.51 crore, while revenue from operations rose 13.40% to Rs 330.80 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live